Menu

Clovis Oncology, Inc. CLVS

Full chart Compare
Set alert

Price alert · CLVS

All alert types
0.08 +0.08

Day range unavailable

52-week range unavailable

Discussion (3636)

Sign in to join the discussion

Febreary,21. 2019 CLVS 6 years ago #3571

Clovis Oncology's Rubraca now available in France; shares up 4% premarket
Feb. 03, 2020 8:44 AM ETClovis Oncology, Inc. (CLVS)By: Mamta Mayani, SA News Editor3 Comments
Clovis Oncology (NASDAQ:CLVS) announces that Rubraca (rucaparib), an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 is now available and reimbursed in France.
Rubraca is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.
With Rubraca now available in France, it is now a treatment option for eligible patients in Germany, England and Italy.
Shares are up 4% premarket.

Febreary,21. 2019 CLVS 6 years ago #3572

I Think So!!! $MART$9x. Pure Manipulation this STOCK.

Many NEWS POSITIVE, and NOTHING.

*Last Friday: 74.000 Share each Director (03). (SEC).

  • Today: In France Approval.
  • Good Revenue.
  • Earnings Per Share. Good Projection 02/24/2020.

“ I CAN BELIEVE!!!!!” ........

Febreary,21. 2019 CLVS 6 years ago #3574

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

Business Wire
February 3, 2020, 5:00 AM GMT-4

Febreary,21. 2019 CLVS 6 years ago #3575

Survey: (clvs), and get more quote of action.

1 - present the earnings fourth quarter first. In February, 24,2020.

2 - subsequently, February 24,2020, submitting the approval of the Fda from sDNA.

3 - or vice versa. (2-1).

Vote: #?

Febreary,21. 2019 CLVS 6 years ago #3578

I hope that two situations will not coincide: 1) The approval of the sDna for the European market. Which is early. and 2) Separately the 4Quarter presentation which the expectations of profits and projections are BIGS. These two situations in favor must be presented separately to see high the share of the action at separate events. Big Money is Coming. $MART$9X. BUT “SURE”.....